Good Lifestyle

Vaccine rolks In the United States had a successful race in recent months. According to disease control and prevention centers (CDC), more than136 million people In the United States have already been fully vaccinated against COVID. Nevertheless, however, there is a concern about emerging variants, withFive variants of concern By circulating already in the United States, experts are worried could be more communicable and more likely to escape current vaccines. Fortunately, vaccine manufacturers have worked to find new ways to combat these variants and others that can emerge the line. In fact, Moderna has just announced a big change to its vaccine to do this - and this could affect your VVID vaccination in 2022.

RELATED:Moderna has just made a major announcement on its vaccine.

Moderna collaborates with Drugmaker based in Switzerland Lonza since May 2020, but they have just announced on June 2nd that they areExpand By creating a new production line at the installation of Lonza Geleen in the Netherlands - and with a significant change against the Moderna vaccine. According to the announcement, the new production line will make ingredients up to 300 million doses per year to 50 micrograms per dose, which means to halve the current vaccine dose.

Moderna delivered doses to an approved100 micrograms per dose in the United Statesand Europe. But oneThe spokesman of Moderna told Reuters Following the announcement of the new production of Lonza, "we suppose that at 2022, we will have a mix of doses on the market."

Reuters says that Biotech has long been studying lower dose versions of its vaccine - initially to stretch the vaccine supply. CBS reported in January that the United States was consideringCut doses of modernly vaccine in two Accelerate the deployment of the vaccine. At the time,Moncef Slaoui, the former Federal Vaccine Program Manager Operation of Chain Speed ​​under the Trump Administration, saidFace the nation That a half-dose of moderna vaccine "induces an identical immune response" at the total dose. However, the Food and Drug Administration (FDA) has never ended up approving change.

RELATED:For more information up to date, sign up for our daily newsletter.

But while half of the doses are no longer necessary to accelerate the deployment of vaccines in the United States, they can be the right choice to combat vaccine variants. Moderna recently indicated that half of the doses showed promising results in terms of reminder plans for emerging variants. The Biotech company said in May 5th, indicate that only one dose of booster of 50 micrograms proved to beIncrease the neutralization of antibody responses In participants in clinical trials previously vaccinated against two variations of concern: South Africa variant B.1.351 and variant Brazil p.1.

"We are encouraged by these new data, which reinforce our confidence that our recall strategy must be protective against these newly detected variants," the CEO of ModernaStéphane Bantel said in a statement.

According to Reuters, not only half of the doses will be considered for variant targeting recall plans, but lower doses can also be given to children likely to not require a complete dose of 100 micrograms.

RELATED:If you have modern, it's when you need a booster, Director of Management.